トランスクリプトミクス市場- 世界の産業規模、シェア、動向、機会、予測、コンポーネント別、技術別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

トランスクリプトミクスの世界市場規模は2024年に75億3,000万米ドルで、予測期間中のCAGRは5.33%で2030年には102億8,000万米ドルに達すると予測されています。

トランスクリプトミクスの世界市場は、発展途上国における遺伝性疾患の診断のためのRNAシーケンスとNGSの応用の拡大により、著しい成長を遂げています。さらに、新しいマイクロアレイ技術の導入による新技術開発のための政府組織によるイニシアチブと投資の増加により、トランスクリプトミクスの需要は世界のさまざまな地域で大幅に増加しています。さらに、新技術の採用が増加し、治療のための個別化医療に対する需要が高まっていることも、トランスクリプトミクスの需要を増加させ、市場の成長を促進すると予想されます。

さらに、バイオ製薬企業の増加や研究開発への支出の増加は、トランスクリプトミクスの需要をさらに増加させ、市場の成長を支えるものと予想されます。米国では毎年4分半に1人の割合で先天性欠損症を持つ赤ちゃんが生まれており、毎年米国で生まれる赤ちゃんの33人に1人がその影響を受けています。これは約12万人の赤ちゃんに相当します。トランスクリプトミクスはトランスクリプトームの研究であり、ゲノムによって産生されるRNA転写物の完全な集合です。

市場促進要因

ハイスループットシーケンス技術の進歩

主な市場課題

複雑なデータ解釈とバイオインフォマティクスのボトルネック

主な市場動向

疾患調査におけるマルチオミクスアプローチの統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 世界のトランスクリプトミクス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • コンポーネント別（機器、消耗品、ソフトウェア、サービス）
  • 技術別（次世代シーケンシング、ポリメラーゼ連鎖反応、マイクロアレイ、In-Situハイブリダイゼーション、その他）
  • 用途別（創薬・開発、細胞生物学、単一細胞解析、遺伝子発現、その他）
  • エンドユーザー別（バイオテクノロジー・製薬企業、学術・研究機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • コンポーネント別
  • 技術別
  • 用途別
  • エンドユーザー別
  • 地域別

第7章 北米のトランスクリプトミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州のトランスクリプトミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域のトランスクリプトミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米のトランスクリプトミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカのトランスクリプトミクス市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威/サービス

第15章 SWOT分析：世界のトランスクリプトミクス市場

第16章 競合情勢

• Agilent Technologies, Inc.
• ANGLE plc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• Fluidigm Corporation
• BioSypder, Inc.
• Danaher Corporation
• 10x Genomics, Inc.
• Pacific Biosciences of California, Inc.
• NanoString Technologies, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Transcriptomics Market was valued at USD 7.53 billion in 2024 and is expected to reach USD 10.28 billion by 2030 with a CAGR of 5.33% during the forecast period. The global market for Transcriptomics is experiencing significant growth, driven by the growing application of RNA sequencing and NGS for the diagnosis of genetic illness in the developing countries. Additionally, growing initiative and investments by government organizations for developing new technology, with the introduction of new microarray technology have significantly increased the demand for transcriptomics across different parts of the globe. Additionally, the rising adoption of new technology and growing demand for personalized medicine for treatments are further expected to increase the demand for transcriptomics, thereby fuelling the market growth.

Furthermore, increasing number of biopharmaceutical companies and growing expenditure on research and development are further expected to increase the demand for transcriptomics, thereby supporting the market growth. Every 4 1/2 minutes, a baby is born with a birth defect in United States every year and affects 1 in every 33 babies born in the United States each year. That translates into about 120,000 babies. Transcriptomics is the study of the transcriptome, which is the complete set of RNA transcripts that are produced by the genome.

Key Market Drivers

Advancements in High-Throughput Sequencing Technologies

The rapid evolution and increased affordability of high-throughput sequencing technologies-particularly RNA sequencing (RNA-seq)-have significantly propelled the growth of the global transcriptomics market. RNA-seq enables the precise quantification of transcripts and discovery of novel RNA species across various sample types, thereby facilitating large-scale gene expression profiling in both basic research and clinical applications. Governments across the globe are investing heavily in next-generation sequencing (NGS) infrastructure. For instance, the U.S. National Institutes of Health (NIH) allocated over $1.5 billion in 2023 for initiatives linked to genomic medicine, including transcriptomics. NIH's All of Us Research Program has specifically emphasized the inclusion of RNA expression data to understand disease biology across diverse populations.

In addition, transcriptomics technologies are increasingly integrated into disease biomarker discovery, drug development pipelines, and personalized medicine. Projects such as the Genotype-Tissue Expression (GTEx) Project by the NIH have generated comprehensive gene expression datasets, enabling researchers to map tissue-specific gene expressions and variation across populations. The plummeting costs of RNA-seq-from over $1,000 per sample a decade ago to less than $100 today-have democratized access to these technologies. This price drop is particularly impactful for academic institutions and biotech companies in developing nations, driving adoption at a global scale. Moreover, automation in sample preparation, data analysis, and bioinformatics pipelines further accelerates throughput and reduces labor costs, enhancing scalability.

Key Market Challenges

Complex Data Interpretation and Bioinformatics Bottlenecks

Despite the advances in transcriptomic technologies, data complexity and bioinformatics limitations remain substantial challenges hindering market growth. Transcriptomic analyses-especially using RNA-seq-generate enormous volumes of data, often reaching hundreds of gigabytes per sample. Extracting meaningful insights from these datasets requires sophisticated algorithms, powerful computational infrastructure, and expertise in bioinformatics. The European Bioinformatics Institute (EMBL-EBI) and NIH's National Center for Biotechnology Information (NCBI) host large-scale transcriptomic repositories such as GEO (Gene Expression Omnibus) and ArrayExpress. However, interpreting this data requires integration with proteomics, genomics, and clinical phenotypes, which adds further layers of complexity. For many healthcare providers and small research labs, this technical requirement becomes a major barrier.

According to a 2022 survey by the Global Alliance for Genomics and Health (GA4GH), more than 60% of genomics labs identified a shortage of bioinformatics talent as a significant operational bottleneck. Furthermore, inconsistencies in data normalization, quality control, and analysis pipelines often lead to irreproducible results, limiting the translational utility of transcriptomics in clinical settings. Another related challenge is the need for standardized bioinformatics workflows. While initiatives such as the FDA's SEQC (Sequencing Quality Control) Project aim to establish quality benchmarks, globally accepted standards for transcriptomic data interpretation are still evolving. Until data analysis becomes more user-friendly and standardized across platforms, the complexity of transcriptomic datasets will continue to restrain broader adoption in clinical and research domains.

Key Market Trends

Integration of Multi-Omics Approaches in Disease Research

A growing trend in transcriptomics is its integration with other omics technologies, including genomics, proteomics, epigenomics, and metabolomics, to provide a holistic view of biological systems. This multi-omics approach enhances the understanding of complex disease mechanisms by correlating gene expression profiles with protein activity, epigenetic modifications, and metabolic changes. The U.S. National Cancer Institute (NCI) has launched several multi-omics initiatives, including the Human Tumor Atlas Network (HTAN), which maps tumors using transcriptomics, genomics, and imaging. The goal is to understand how tumors evolve over time and how patients respond to therapy, enabling the development of personalized treatment plans.

Similarly, the UK Biobank, backed by the UK government and Wellcome Trust, is increasingly adding transcriptomic data to its already vast genomic and clinical dataset. This allows researchers to connect gene expression patterns with real-world disease outcomes in a population-scale setting. This trend is not limited to developed countries. India's GenomeIndia project, supported by the Department of Biotechnology, is also moving towards the integration of transcriptomics with proteomic and metabolomic data to understand ethnic-specific disease vulnerabilities. Such integrative research helps in discovering novel drug targets, stratifying patients for clinical trials, and predicting disease progression. With advancements in artificial intelligence (AI) and machine learning (ML), multi-omics data integration is becoming more feasible, driving deeper biological insights and fueling demand for transcriptomic technologies.

Key Market Players

• Agilent Technologies, Inc.
• ANGLE plc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• Fluidigm Corporation
• BioSypder, Inc.
• Danaher Corporation
• 10x Genomics, Inc.
• Pacific Biosciences of California, Inc.
• NanoString Technologies, Inc.

Report Scope:

In this report, the Global Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transcriptomics Market, By Component:

• Instruments
• Consumables
• Software & Services

Transcriptomics Market, By Technology:

• Next Generation Sequencing
• Polymerase Chain Reaction
• Microarray
• In-Situ Hybridization
• Others

Transcriptomics Market, By Application:

• Drug Discovery & Development
• Cell Biology
• Single Cell Analysis
• Gene Expression
• Others

Transcriptomics Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Transcriptomics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Transcriptomics Market.

Available Customizations:

Global Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Transcriptomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component (Instruments, Consumables, Software & Services)
  • 6.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization, Others)
  • 6.2.3. By Application (Drug Discovery & Development, Cell Biology, Single Cell Analysis, Gene Expression, Others)
  • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Component
  • 6.3.2. By Technology
  • 6.3.3. By Application
  • 6.3.4. By End User
  • 6.3.5. By Region

7. North America Transcriptomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Transcriptomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Transcriptomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Transcriptomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User

8. Europe Transcriptomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Transcriptomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Transcriptomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Transcriptomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Transcriptomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Transcriptomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Asia-Pacific Transcriptomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Transcriptomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. India Transcriptomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Transcriptomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Transcriptomics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Component
      • 9.3.4.2.2. By Technology
      • 9.3.4.2.3. By Application
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Transcriptomics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Component
      • 9.3.5.2.2. By Technology
      • 9.3.5.2.3. By Application
      • 9.3.5.2.4. By End User

10. South America Transcriptomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transcriptomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Transcriptomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Transcriptomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Middle East and Africa Transcriptomics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Component
  • 11.2.2. By Technology
  • 11.2.3. By Application
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Transcriptomics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Component
      • 11.3.1.2.2. By Technology
      • 11.3.1.2.3. By Application
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Transcriptomics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Component
      • 11.3.2.2.2. By Technology
      • 11.3.2.2.3. By Application
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Transcriptomics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Component
      • 11.3.3.2.2. By Technology
      • 11.3.3.2.3. By Application
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Transcriptomics Market

16. Competitive Landscape

• 16.1. Agilent Technologies, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. ANGLE plc.
• 16.3. Bio-Rad Laboratories, Inc.
• 16.4. Becton, Dickinson, and Company
• 16.5. Fluidigm Corporation
• 16.6. BioSypder, Inc.
• 16.7. Danaher Corporation
• 16.8. 10x Genomics, Inc.
• 16.9. Pacific Biosciences of California, Inc.
• 16.10. NanoString Technologies, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer